サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1661004

創傷ケアバイオロジクス市場レポート：製品タイプ、創傷タイプ、用途、エンドユーザー、地域別、2025年～2033年

Wound Care Biologics Market Report by Product, Wound Type, Application, End-User, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.66円
創傷ケアバイオロジクス市場レポート：製品タイプ、創傷タイプ、用途、エンドユーザー、地域別、2025年～2033年
出版日: 2025年02月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

創傷ケアバイオロジクスの世界市場規模は2024年に23億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに43億米ドルに達し、2025～2033年の成長率（CAGR）は7.05％になると予測しています。同市場は、慢性創傷の増加、バイオテクノロジーの進歩、患者中心の低侵襲ソリューションへのシフトを背景に着実な成長を遂げており、創傷管理における革新的な生物学的療法の需要を牽引しています。

創傷ケアバイオロジクス市場分析：

市場の成長と規模：世界市場は、慢性創傷、熱傷、外科手術の増加によって力強い成長を遂げており、市場規模の大幅な拡大に寄与しています。

主な市場促進要因：慢性疾患の増加、高齢化、複雑な創傷治癒に対応する生物学的療法による高度創傷ケアソリューションの需要などが挙げられます。

技術の進歩：バイオテクノロジー、再生医療、先端材料の統合における急速な技術進歩は、より効果的で個別化された創傷治療用生物製剤の開発に貢献しています。

産業への応用：これらの生物製剤は、潰瘍、外科的創傷、熱傷、外傷性創傷など、さまざまなタイプの創傷に応用されています。

地理的動向：急速な工業化、ヘルスケア投資の増加、人口の増加を背景に、アジア太平洋地域が最大の市場セグメントとなっています。

競合情勢：競合各社は研究開発に積極的に投資し、戦略的提携を結び、買収を通じて世界の事業基盤を拡大し、競争市場におけるリーダーとしての地位を確立しています。

課題と機会：課題としては、変化への抵抗、データ・セキュリティへの懸念、普及の必要性などが挙げられます。一方、機会としては、持続可能性に焦点を当てたソリューション、進化する消費者の需要への対応、世界なサプライチェーンの複雑性の克服などが挙げられます。

将来の展望：今後も各産業界が高度な創傷ケアソリューションを優先するため、市場の持続的な成長が期待されます。技術的進歩の継続、用途の拡大、持続可能性の重視により、市場は今後も進化と革新を続けていくものと思われます。

創傷ケアバイオロジクス市場動向

慢性創傷と潰瘍の増加

高齢化、糖尿病、血管疾患などの要因によって慢性創傷や潰瘍の有病率が高まっていることが、市場の主要な促進要因となっています。慢性創傷に関連する世界のヘルスケア負担の増加に伴い、高度な治療ソリューションに対する需要が高まっています。成長因子、細胞外マトリックス、幹細胞をベースとした治療法などの創傷治療用生物製剤は、治癒プロセスを促進し、従来の治療にしばしば抵抗する慢性創傷の複雑性に対処するための有望な手段を提供します。これらの革新的な生物製剤は、慢性創傷管理に不可欠な組織再生の促進や炎症の抑制に重要な役割を果たします。血小板由来成長因子や上皮成長因子のような成長因子は、細胞増殖と組織修復を刺激します。細胞外マトリックスは細胞移動と組織再構築の足場となり、創傷閉鎖を促進します。幹細胞治療は、組織再生を促進し、免疫反応を調節することで貢献します。これらの生物学的製剤は個別化された治療が可能であるため、多様な創傷特性を持つ患者の治療成績を最適化することができます。創傷治療の生物学的製剤の研究開発を継続することで、更なる飛躍が期待され、進化するヘルスケア分野における慢性創傷治療の展望が大きく変わる。

バイオテクノロジーと再生医療の急速な進歩

バイオテクノロジーと再生医療における飛躍的な進歩が市場を前進させています。組織工学、生体材料、細胞メカニズムの解明における革新は、治癒能力を強化した生物学的治療法の開発につながった。遺伝子治療や組織再生などの最先端技術を創傷治療の生物学的製剤に統合することは、複雑な創傷に対してより効果的で個別化された治療法を提供するという業界のコミットメントを強調するものです。さらに、人工知能とバイオテクノロジーの融合により、新規治療ターゲットの同定が容易になり、個々の患者プロファイルに合わせた生物製剤の開発が促進されています。遺伝子レベルで細胞機能を改変できる遺伝子治療は、慢性創傷の根本的な原因に対処する上で有望です。高度な画像診断ツールに導かれた組織再生技術は、的確な介入を可能にします。これらの科学的フロンティアが拡大するにつれ、テクノロジーと生物学的製剤の相乗効果によって創傷治療の展望が大きく変わりつつあります。この融合は既存の治療の有効性を高めるだけでなく、創傷治療の未来を再定義する画期的な解決策への道を開く。

低侵襲で患者中心のアプローチへの注目の高まり

低侵襲で患者中心の創傷治療アプローチへのパラダイムシフトが生物学的製剤の採用を後押ししています。患者やヘルスケアプロバイダーは、より早い治癒を促し、痛みを軽減し、全体的なQOLを向上させるような介入をますます求めるようになっています。創傷治療の生物学的製剤は自然治癒プロセスを刺激する能力を持ち、この動向に合致しています。業界が患者の快適性と転帰を向上させる治療を優先し続ける中、創傷ケアにおける生物学的製剤の需要は拡大し、創傷管理に対するより全体的で個別化されたアプローチが促進されると予想されます。このような患者中心の治療へのシフトは、生物学的製剤の有効性だけでなく、従来の治療と比べて利便性が高く侵襲性が低いことにも反映されています。生物学的製剤は外傷を最小限に抑え、患者の早期回復と不快感の軽減を可能にする的を絞った治療法です。生活の質を向上させることに重点を置くことは、使いやすい適用方法や在宅ケアの選択肢の開発にも及んでいます。ヘルスケアが個人のニーズを優先するように進化する中、創傷治療の生物学的製剤の軌跡はこの患者中心のパラダイムとシームレスに一致し、先進的な治療が創傷を治すだけでなく、治療を受ける人々の全体的な幸福と満足を優先する変革の時代を示しています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の創傷ケアバイオロジクス市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場内訳：製品別
  • 市場内訳：創傷タイプ別
  • 市場内訳：用途別
  • 市場内訳：エンドユーザー別
  • 市場内訳：地域別
  • 市場予測

第6章 市場内訳：製品別

  • 生物学的皮膚代替品
    • 市場動向
    • 市場内訳：タイプ別
      • ヒトドナー組織由来製品
      • 無細胞動物由来製品
      • 生合成製品
    • 市場予測
  • 外用剤
    • 市場動向
    • 市場予測

第7章 市場内訳：創傷タイプ別

  • 潰瘍
    • 市場動向
    • 市場内訳：タイプ別
      • 糖尿病性足潰瘍
      • 静脈性潰瘍
      • 褥瘡
      • その他
    • 市場予測
  • 外科手術および外傷による創傷
    • 市場動向
    • 市場予測
  • バーンズ
    • 市場動向
    • 市場予測

第8章 市場内訳：用途別

  • 急性創傷
    • 市場動向
    • 市場予測
  • 慢性創傷
    • 市場動向
    • 市場予測
  • 手術創
    • 市場動向
    • 市場予測

第9章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • ASCs
    • 市場動向
    • 市場予測
  • 熱傷センターと創傷クリニック
    • 市場動向
    • 市場予測

第10章 市場内訳：地域別

  • アジア太平洋地域
    • 市場動向
    • 市場予測
  • 欧州
    • 市場動向
    • 市場予測
  • 北米
    • 市場動向
    • 市場予測
  • 中東・アフリカ
    • 市場動向
    • 市場予測
  • ラテンアメリカ
    • 市場動向
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Smith & Nephew
    • Molnlycke Health Care
    • Integra lifesciences
    • Osiris Therapeutics
    • Avita Medical
    • ConvaTec Group
    • Cytori Therapeutics
    • Mylan
    • Johnson & Johnson
    • Leap Therapeutics
    • Nuo Therapeutics
    • Mallinckrodt
    • Wright Medical
    • Mimedx Group
    • Solsys Medical
図表

List of Figures

  • Figure 1: Global: Wound Care Biologics Market: Major Drivers and Challenges
  • Figure 2: Global: Wound Care Biologics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Wound Care Biologics Market: Breakup by Product (in %), 2024
  • Figure 4: Global: Wound Care Biologics Market: Breakup by Wound Type (in %), 2024
  • Figure 5: Global: Wound Care Biologics Market: Breakup by Application (in %), 2024
  • Figure 6: Global: Wound Care Biologics Market: Breakup by End-User (in %), 2024
  • Figure 7: Global: Wound Care Biologics Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Wound Care Biologics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Wound Care Biologics Industry: SWOT Analysis
  • Figure 10: Global: Wound Care Biologics Industry: Value Chain Analysis
  • Figure 11: Global: Wound Care Biologics Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Wound Care Biologics (Biologic Skin Substitutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Wound Care Biologics (Biologic Skin Substitutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Wound Care Biologics (Topical Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Wound Care Biologics (Topical Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Wound Care Biologics (Ulcers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Wound Care Biologics (Ulcers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Wound Care Biologics (Surgical and Traumatic Wounds) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Wound Care Biologics (Surgical and Traumatic Wounds) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Wound Care Biologics (Burns) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Wound Care Biologics (Burns) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Wound Care Biologics (Acute Wound) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Wound Care Biologics (Acute Wound) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Wound Care Biologics (Chronic Wound) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Wound Care Biologics (Chronic Wound) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Wound Care Biologics (Surgical Wound) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Wound Care Biologics (Surgical Wound) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Wound Care Biologics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Wound Care Biologics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Wound Care Biologics (ASCs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Wound Care Biologics (ASCs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Wound Care Biologics (Burn Centres and Wound Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Wound Care Biologics (Burn Centres and Wound Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Asia Pacific: Wound Care Biologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Asia Pacific: Wound Care Biologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Wound Care Biologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Wound Care Biologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Europe: Wound Care Biologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Europe: Wound Care Biologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Middle East and Africa: Wound Care Biologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Middle East and Africa: Wound Care Biologics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Latin America: Wound Care Biologics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Latin America: Wound Care Biologics Market Forecast: Sales Value (in Million USD), 2025-2033

List of Tables

  • Table 1: Global: Wound Care Biologics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Wound Care Biologics Market Forecast: Breakup by Product (in Million USD), 2025-2033
  • Table 3: Global: Wound Care Biologics Market Forecast: Breakup by Wound Type (in Million USD), 2025-2033
  • Table 4: Global: Wound Care Biologics Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 5: Global: Wound Care Biologics Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 6: Global: Wound Care Biologics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Wound Care Biologics Market Structure
  • Table 8: Global: Wound Care Biologics Market: Key Players
目次
Product Code: SR112025A1489

The global wound care biologics market size reached USD 2.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.3 Billion by 2033, exhibiting a growth rate (CAGR) of 7.05% during 2025-2033. The market is experiencing steady growth driven by the rising incidence of chronic wounds, advancements in biotechnology, and a shift towards minimally invasive patient-centric solutions, which is driving demand for innovative biologic therapies in wound management.

Wound Care Biologics Market Analysis:

Market Growth and Size: The global market is experiencing robust growth, driven by an increasing prevalence of chronic wounds, burns, and surgical procedures, contributing to a significant expansion in market size.

Major Market Drivers: Key drivers include the rising incidence of chronic diseases, aging populations, and the demand for advanced wound care solutions, with biologic therapies addressing the complexities of wound healing.

Technological Advancements: Rapid technological advancements in biotechnology, regenerative medicine, and the integration of advanced materials contribute to the development of more effective and personalized wound care biologics.

Industry Applications: These biologics find application across various wound types, including ulcers, surgical wounds, burns, and traumatic wounds, reflecting their versatility and effectiveness in managing diverse clinical scenarios.

Geographical Trends: Asia Pacific emerges as the largest market segment, driven by rapid industrialization, increasing healthcare investments, and a growing population, while North America and Europe maintain significant market presence.

Competitive Landscape: Key players are actively investing in research and development, forming strategic collaborations, and expanding their global footprint through acquisitions, positioning themselves as leaders in the competitive market.

Challenges and Opportunities: Challenges include resistance to change, data security concerns, and the need for widespread adoption, while opportunities lie in sustainability-focused solutions, meeting evolving consumer demands, and navigating global supply chain complexities.

Future Outlook: The future outlook for the market appears promising, with sustained growth anticipated as industries continue to prioritize advanced wound care solutions. Continued technological advancements, expanding applications, and a focus on sustainability position the market for continued evolution and innovation in the coming years.

Wound Care Biologics Market Trends:

Increasing incidence of chronic wounds and ulcers

The growing prevalence of chronic wounds and ulcers, fueled by factors such as aging populations, diabetes, and vascular diseases, is a major driver for the market. As the global healthcare burden associated with chronic wounds rises, there is a heightened demand for advanced therapeutic solutions. Wound care biologics, including growth factors, extracellular matrices, and stem cell-based therapies, offer promising avenues for accelerating the healing process and addressing the complexities of chronic wounds that often resist conventional treatments. These innovative biologics play a crucial role in promoting tissue regeneration and reducing inflammation, essential aspects in chronic wound management. Growth factors, like platelet-derived growth factor and epidermal growth factor, stimulate cell proliferation and tissue repair. Extracellular matrices provide a scaffold for cell migration and tissue rebuilding, enhancing wound closure. Stem cell therapies contribute by promoting tissue regeneration and modulating the immune response. The personalized nature of these biologics allows for tailored treatments, optimizing outcomes for patients with diverse wound characteristics. Continued research and development in wound care biologics hold the promise of further breakthroughs, revolutionizing the landscape of chronic wound management in the evolving field of healthcare.

Rapid advancements in biotechnology and regenerative medicine

Significant strides in biotechnology and regenerative medicine are propelling the market forward. Innovations in tissue engineering, biomaterials, and the understanding of cellular mechanisms have led to the development of biological therapies with enhanced healing capabilities. The integration of cutting-edge technologies, such as gene therapy and tissue regeneration, into wound care biologics underscores the industry's commitment to providing more effective and personalized treatment options for complex wounds. Moreover, the convergence of artificial intelligence and biotechnology has facilitated the identification of novel therapeutic targets, fostering the creation of biologics tailored to individual patient profiles. Gene therapy, with its ability to modify cellular functions at a genetic level, holds promise in addressing underlying causes of chronic wounds. Tissue regeneration techniques, guided by advanced imaging and diagnostic tools, enable precise interventions. As these scientific frontiers expand, the synergy between technology and biologics is reshaping the wound care landscape. This amalgamation not only augments the efficacy of existing treatments but also opens avenues for groundbreaking solutions that may redefine the future of wound care.

Rising focus on minimally invasive and patient-centric approaches

A paradigm shift towards minimally invasive and patient-centric wound care approaches is driving the adoption of biologics. Patients and healthcare providers increasingly seek interventions that promote faster healing, reduce pain, and improve overall quality of life. Wound care biologics, with their capacity to stimulate natural healing processes, align with this trend. As the industry continues to prioritize therapies that enhance patient comfort and outcomes, the demand for biologic solutions in wound care is expected to grow, fostering a more holistic and personalized approach to wound management. This shift towards patient-centric care is not only reflected in the efficacy of biologics but also in their convenience and reduced invasiveness compared to traditional treatments. Biologics offer targeted interventions that minimize trauma, supporting quicker recovery and decreased discomfort for patients. The emphasis on enhancing quality of life extends to the development of user-friendly application methods and home-based care options. As healthcare evolves to prioritize individual needs, the trajectory of wound care biologics aligns seamlessly with this patient-centric paradigm, marking a transformative era where advanced therapies not only heal wounds but also prioritize the overall well-being and satisfaction of those undergoing treatment.

Wound Care Biologics Industry Segmentation:

Breakup by Product:

  • Biologic Skin Substitutes
  • Human Donor Tissue-Derived Products
  • Acellular Animal-Derived Products
  • Biosynthetic Products
  • Topical Agents

Biologic skin substitutes account for the majority of the market share

Breakup by Wound Type:

  • Ulcers
  • Diabetic Foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Others
  • Surgical and Traumatic Wounds
  • Burns

Ulcers hold the largest share in the industry

Breakup by Application:

  • Acute Wound
  • Chronic Wound
  • Surgical Wound

Chronic wound represents the leading market segment

Breakup by End-User:

  • Hospitals
  • ASCs
  • Burn Centres and Wound Clinics

Hospitals represents the leading market segment

Breakup by Region:

  • Asia Pacific
  • Europe
  • North America
  • Middle East and Africa
  • Latin America

North America leads the market, accounting for the largest wound care biologics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include Asia Pacific, Europe, North America, Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Smith & Nephew
  • Molnlycke Health Care
  • Integra lifesciences
  • Osiris Therapeutics
  • Avita Medical
  • ConvaTec Group
  • Cytori Therapeutics
  • Mylan
  • Johnson & Johnson
  • Leap Therapeutics
  • Nuo Therapeutics
  • Mallinckrodt
  • Wright Medical
  • Mimedx Group
  • Solsys Medical

Key Questions Answered in This Report:

  • How has the global wound care biologics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global wound care biologics market?
  • What is the impact of each driver, restraint, and opportunity on the global wound care biologics market?
  • What are the key regional markets?
  • Which countries represent the most attractive wound care biologics market?
  • What is the breakup of the market based on the product?
  • Which is the most attractive product in the wound care biologics market?
  • What is the breakup of the market based on the wound type?
  • Which is the most attractive wound type in the wound care biologics market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the wound care biologics market?
  • What is the breakup of the market based on the end-user?
  • Which is the most attractive end-user in the wound care biologics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global wound care biologics market?"

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Wound Care Biologics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Product
  • 5.5 Market Breakup by Wound Type
  • 5.6 Market Breakup by Application
  • 5.7 Market Breakup by End-User
  • 5.8 Market Breakup by Region
  • 5.9 Market Forecast

6 Market Breakup by Product

  • 6.1 Biologic Skin Substitutes
    • 6.1.1 Market Trends
    • 6.1.2 Market Breakup by Type
      • 6.1.2.1 Human Donor Tissue-Derived Products
      • 6.1.2.2 Acellular Animal-Derived Products
      • 6.1.2.3 Biosynthetic Products
    • 6.1.3 Market Forecast
  • 6.2 Topical Agents
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Wound Type

  • 7.1 Ulcers
    • 7.1.1 Market Trends
    • 7.1.2 Market Breakup by Type
      • 7.1.2.1 Diabetic Foot Ulcers
      • 7.1.2.2 Venous Ulcers
      • 7.1.2.3 Pressure Ulcers
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Surgical and Traumatic Wounds
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Burns
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Acute Wound
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Chronic Wound
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Surgical Wound
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 ASCs
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Burn Centres and Wound Clinics
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 Asia Pacific
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Europe
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 North America
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Middle East and Africa
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast
  • 10.5 Latin America
    • 10.5.1 Market Trends
    • 10.5.2 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porter's Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Smith & Nephew
    • 15.3.2 Molnlycke Health Care
    • 15.3.3 Integra lifesciences
    • 15.3.4 Osiris Therapeutics
    • 15.3.5 Avita Medical
    • 15.3.6 ConvaTec Group
    • 15.3.7 Cytori Therapeutics
    • 15.3.8 Mylan
    • 15.3.9 Johnson & Johnson
    • 15.3.10 Leap Therapeutics
    • 15.3.11 Nuo Therapeutics
    • 15.3.12 Mallinckrodt
    • 15.3.13 Wright Medical
    • 15.3.14 Mimedx Group
    • 15.3.15 Solsys Medical